Eli Lilly Says Foundayo Reduced Sleep Apnea Severity in Late-Stage Program
Eli Lilly said its oral weight-loss drug Foundayo significantly reduced obstructive sleep apnea severity and met the program’s primary endpoint.
By Connor HartEli Lilly said its oral weight-loss drug Foundayo significantly reduced the severity of obstructive sleep apnea in a late-stage clinical program, potentially expanding the drug's use beyond obesity treatment.The pharmaceutical company on Monday said Foundayo met its primary endpoint i…